ATHENS, Ga. — ArunA Biomedical, Inc. today announced the signing of a product manufacturing and distribution agreement with Life Technologies Corporation headquartered in Carlsbad, CA. The non-exclusive multi-year agreement includes ArunA’s human neural cells that are produced using ArunA’s exclusively licensed patented mono-layer technology platform. The agreement enables Life Technologies to provide ArunA’s unique human embryonic stem cell-derived neural products to its customers and provide customized screening services using ArunA products and technology. Additional ArunA human cellular products may be added to the agreement in the future.

Steve Stice, Chief Scientific Officer for ArunA commented, “We are pleased to enter into this agreement with Life Technologies to enhance the distribution of our products to the academic and research communities. Life Technologies is a leader in stem cell research and neurobiology arenas and has a broad reach to both domestic and global markets which we expect will lead to more opportunities for our stem cell products. We have seen increased customer interest for our products as researchers continue the transition to human-based cellular products to reduce the level of animal testing, to achieve improved accuracy of pre-clinical testing and to reduce costs and development lead times.”

ArunA is a privately held early stage biotechnology corporation dedicated to advancing drug discovery and basic research through the development and commercialization of innovative products and services derived from human stem cells.

Products are For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use.